Total company creates a leading foreign injection platform with over 75 outpatient locations in 14 states across the US
Phoenix & Taylorsville, Utah, August 13, 2025 – (Business Wire) – Aleracare is a leading provider of infusion and specialty pharmacy services across the United States, and Pure Healthcare offers Pure Healthcare, a leading medical group that provides medical services for individuals with complex chronic conditions such as Rheumatoid arthritis, Crohnes edised, and Alzhune disease. The company has concluded a decisive merger agreement. The terms of the transaction have not been disclosed.
The proposed merger creates an unprecedented opportunity to provide high-quality patient care, improve clinical outcomes, and increase the availability of infusion services that reduce overall costs across the health care system.
Founded in 2019, Aleracare's core business lines include outpatient injection centres, home infusion therapy and specialized pharmacies. Managed in a convenient, accessible patient-first location, Aleracare focuses on maintaining trustworthy partner status with doctors, payers, drug dealers and pharmaceutical manufacturers. The company is rapidly expanding to more than 30 outpatient injection centres nationwide and is a selective provider of injection services for needs and medically complex populations.
Founded in 2018, Pure Healthcare is committed to transforming the healthcare industry by making infusion therapy more affordable and accessible. Pure specializes in the treatment of chronic and autoimmune conditions such as Alzheimer's disease, multiple sclerosis, and rheumatoid arthritis, providing innovative and quality care tailored to the individual's needs. Its flagship product, Pure Infusion Suites, has expanded to 43 locations in 14 states. These state-of-the-art suites prioritize patient comfort with private rooms, snacks and entertainment, all significantly reducing the cost of infusion services. Pure health care also reduces the administrative burden of referring providers by supporting patient approval, promoting strong partnerships with insurance companies, and ensuring a seamless and efficient care journey from referrals to treatment.
The transaction is expected to close in the fourth quarter of 2025 and is subject to customary closure conditions, such as the expiration or termination of applicable wait periods under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.
The story continues
